XML 90 R79.htm IDEA: XBRL DOCUMENT v3.4.0.3
SEGMENT INFORMATION, Segment Information Reconciled to Consolidated Financial Results (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Segment Reporting Information [Line Items]    
Total revenues $ 225,508 $ 143,096
Cost of revenues 122,918 83,862
Selling, general and administrative 44,298 50,160
Research and development 19,022 14,962
Patent litigation 1,319 960
Income (loss) before income taxes (17,494) (10,705)
Corporate and Other    
Segment Reporting Information [Line Items]    
Selling, general and administrative 25,706 31,018
Income (loss) before income taxes (81,151) (34,875)
Impax Generics    
Segment Reporting Information [Line Items]    
Total revenues 170,079 128,741
Impax Generics | Operating Segments    
Segment Reporting Information [Line Items]    
Total revenues 170,079 128,741
Cost of revenues 110,122 76,472
Selling, general and administrative 4,774 4,286
Research and development 14,595 10,863
Patent litigation 114 778
Income (loss) before income taxes 40,474 36,342
Impax Specialty Pharma    
Segment Reporting Information [Line Items]    
Total revenues 55,429 14,355
Impax Specialty Pharma | Operating Segments    
Segment Reporting Information [Line Items]    
Total revenues 55,429 14,355
Cost of revenues 12,796 7,390
Selling, general and administrative 13,818 14,856
Research and development 4,427 4,099
Patent litigation 1,205 182
Income (loss) before income taxes $ 23,183 $ (12,172)